Identify genetic causes of Parkinson
- Trial ID
- NCT05721911
- Official Title
- Implementing a National Biobank of Genetic, Sporadic and Prodromic Parkinson's Disease With Whole Genome Analysis and Functional Assessment of Polygenic Inheritance by iPSC Technology
- Goal
- Identify genetic causes of Parkinson
- Status
- RECRUITING
- Sponsor
- IRCCS San Raffaele
- Study Type
- OBSERVATIONAL
- Enrollment
- 230 participants
- Conditions
- Parkinson Disease, REM Sleep Behavior Disorder
- Interventions
- whole genome sequencing
Plain-Language Summary
The goal is to build a national biobank linking whole genome data and lab-grown cell models to figure out how combinations of genetic variants influence Parkinson's risk, progression, and the link with REM sleep behavior disorder. Participants give samples for whole genome sequencing to find known and new risk variants and for making induced pluripotent stem cells, which are turned into neurons so researchers can test how a person’s unique polygenic profile alters cell function; the project is observational and does not change your Parkinson's medications. Adults 18 and older are eligible, including people with Parkinson's who have at least two cardinal signs with tremor or bradykinesia and a documented response to L-dopa or dopamine agonists, and people with idiopathic RBD; the study excludes those with dementia, other neurodegenerative diseases, major psychiatric conditions, or prolonged use of certain psychotropic drugs.
Locations
- IRCCS San Raffaele, Milan, Italy, Italy
Frequently Asked Questions
- What is this trial testing?
- This trial is studying whole genome sequencing. The goal is to build a national biobank linking whole genome data and lab-grown cell models to figure out how combinations of genetic variants influence Parkinson's risk, progression, and the link with REM sleep behavior disorder. Participants give samples for whole genome sequencing to find known and new risk variants and for making induced pluripotent stem cells, which are turned into neurons so researchers can test how a person’s unique polygenic profile alters cell function; the project is observational and does not change your Parkinson's medications. Adults 18 and older are eligible, including people with Parkinson's who have at least two cardinal signs with tremor or bradykinesia and a documented response to L-dopa or dopamine agonists, and people with idiopathic RBD; the study excludes those with dementia, other neurodegenerative diseases, major psychiatric conditions, or prolonged use of certain psychotropic drugs.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years and 4 months.